Age, Biography and Wiki
Gianluca Tognon was born on 21 May, 1976 in Italy, is a Food scientist, researcher, public health expert, author and speaker.. Discover Gianluca Tognon's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is He in this year and how He spends money? Also learn how He earned most of networth at the age of 44 years old?
|Occupation||Food scientist, researcher, public health expert, author and speaker.|
|Age||45 years old|
|Born||21 May 1976|
We recommend you to check the complete list of Famous People born on 21 May. He is a member of famous with the age 45 years old group.
Gianluca Tognon Height, Weight & Measurements
At 45 years old, Gianluca Tognon height not available right now. We will update Gianluca Tognon's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
|Body Measurements||Not Available|
|Eye Color||Not Available|
|Hair Color||Not Available|
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
Gianluca Tognon Net Worth
His net worth has been growing significantly in 2020-2021. So, how much is Gianluca Tognon worth at the age of 45 years old? Gianluca Tognon’s income source is mostly from being a successful . He is from Italy. We have estimated Gianluca Tognon's net worth, money, salary, income, and assets.
|Net Worth in 2021||$1 Million - $5 Million|
|Salary in 2020||Under Review|
|Net Worth in 2019||Pending|
|Salary in 2019||Under Review|
|Source of Income|
Gianluca Tognon Social Network
|Wikipedia||Gianluca Tognon Wikipedia|
Gianluca Tognon is an Italian food scientist, researcher, public health expert, author and speaker. In 2017 he has founded the consulting company The Food Scientist, which is based in Sweden.
From April 2010 to March 2017 he worked at the Department of Public Health and Community Medicine at the University of Gothenburg (Sweden). He has published several scientific manuscripts on the association between adherence to the Mediterranean diet and longevity as well as chronic disease risk in Swedish and Danish population studies. In addition, his research has also highlighted that milk intake is a risk factor for mortality, whereas cheese and fermented milk intake have the opposite association and he was invited to speak by Harvard university, the Italian multinational company Barilla SpA and European Medical Association. In 2017 Gianluca Tognon founded his own company called The Food Scientist.
In November 2005 he joined the Cancer Prevention and Research Institute and worked as researcher in the Epidemiology unit where he worked within two EU projects: the Diogenes (Diet, obesity and genes) and the Idames (Innovative dietary assessment methods for epidemiological studies and public health).
During 2004 and 2005 he has worked at the Department of Food Safety of the University of Milan, where he developed a new technique for mycotoxin identification based on the electronic nose.
Gianluca Tognon has obtained a degree in Biological Sciences from the University of Pavia in 2000. The title of his dissertation was Effects of the antitumor drug Paclitaxel on human colon cancer. In 2003 he has obtained a specialist degree in Pharmacological research from Regione Lombardia (Italy). In 2005 he has completed a Medical specialty degree in Food science and human nutrition at the University of Pavia. Tognon has also been rewarded with the titles of Advanced speaker and Advanced communicator by the American association Toastmasters Internationals.
Gianluca Tognon started his career in Italy, after the degree in biological sciences at the State University of Pavia. In 2000 he has been granted a fellowship in pharmacology research to work, from September 2000 to September 2003 at the Oncology Department of the “Mario Negri” pharmacological institute in Milan, where he contributed to the testing of two new anticancer drugs (Aplidine and ET-743) developed by the Spanish multinational company Pharma Mar.